A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

October 14, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

October 31, 2027

Conditions
Knee Osteoarthritis
Interventions
BIOLOGICAL

PTP-01

Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.

OTHER

Placebo control / saline vehicle

The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.

Trial Locations (9)

2019

NOT_YET_RECRUITING

Emeritus Research Sydney, Botany

2065

NOT_YET_RECRUITING

Royal North Shore Hospital, St Leonards

2292

RECRUITING

Genesis Research Services, Broadmeadow

3021

RECRUITING

Momentum Clinical Research Sunshine, St Albans

4068

RECRUITING

Momentum Clinical Research Taringa, Taringa

4121

RECRUITING

Momentum Clinical Research Wellers Hill, Tarragindi

4506

NOT_YET_RECRUITING

University of the Sunshine Coast Clinical Trials, Morayfield, Morayfield

4566

NOT_YET_RECRUITING

University of the Sunshine Coast Clinical Trials, Noosa, Noosaville

4575

NOT_YET_RECRUITING

University of the Sunshine Coast Clinical Trials, Birtinya, Birtinya

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Doron Therapeutics Inc.

INDUSTRY